[…] Duchenne muscular dystrophy, and spinal muscular atrophy. While antisense therapy for the potential treatment of FSHD is still in the preclinical stage, we do hear occasional encouraging research results involving […]
An FSHD Antisense Therapy Primer
FSHD Lab Day was empowering for all
Uniting the FSHD Community in Advancing Research by Nizar Saad, PhD, Columbus, Ohio On July 8th, our lab at Nationwide Children’s Hospital (NCH) in Columbus, Ohio, in collaboration with NCH, […]
True Cost of FSHD survey
Preliminary findings from our survey to understand the economic impact of FSHD by June Kinoshita, FSHD Society As a growing number of drugs enter clinical trials for FSHD, a question […]
A trio of promising advances toward treating FSHD
Commentary by Emanuele Mocciaro, PhD, San Raffaele Scientific Institute, Milan, Italy Facioscapulohumeral muscular dystrophy ( FSHD) is caused by the “anomalous” reactivation of the DUX4 gene. DUX4 has an important […]
FSHD Society releases Voice of the Patient Report
[…] severity of disease symptoms and urgent need for treatment LEXINGTON, MASS. (PRWEB) NOVEMBER 12, 2020 The FSHD Society has released its Voice of the Patient Report, a landmark publication based on its […]